// App-Quantinova.ai

O02 : The JAK1-selective inhibitor filgotinib reverses the disease-associated transcriptional profile in the blood of patients with active rheumatoid arthritis

Researchers

Presenter

  • Peter Taylor

Principal Investigators

  • Bryan Downie

  • Luting Zhuo

  • Yevgeniy Gindin

  • Jacqueline Tarrant

  • Ren Galien

  • Jinfeng Liu

  • Amer M Mirza

Medical Centers

  • Cellular Pathology, University of Oxford, Oxford, United Kingdom

  • Gilead Sciences, Gilead Sciences, Foster City, USA

  • Galapagos, Galapagos SASU, Romainville, FRANCE

Locations

  • United Kingdom

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved